Trial Information
Disease	Esophageal or GEJ cancer
Stage of disease/treatment	Stage IV
Prior therapy	One line of prior systemic therapy
Type of study	Phase II randomized
Primary endpoint	Median PFS
Secondary endpoints	Toxicity, median OS, ORR
Investigator’s analysis	Level of activity did not meet planned end point
Additional details of endpoints or study design	Patients were randomized 1:1 to arm A (paclitaxel) or arm B (paclitaxel plus cixutumumab).